HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Timor Baasov Selected Research

Inborn Genetic Diseases (Disease, Hereditary)

1/2017Characterization of new-generation aminoglycoside promoting premature termination codon readthrough in cancer cells.
4/2016Design of Novel Aminoglycoside Derivatives with Enhanced Suppression of Diseases-Causing Nonsense Mutations.
4/2016Targeting Nonsense Mutations in Diseases with Translational Read-Through-Inducing Drugs (TRIDs).
3/2014Long-term nonsense suppression therapy moderates MPS I-H disease progression.
1/2014Designer aminoglycosides that selectively inhibit cytoplasmic rather than mitochondrial ribosomes show decreased ototoxicity: a strategy for the treatment of genetic diseases.
3/2013Development of generic immunoassay for the detection of a series of aminoglycosides with 6'-OH group for the treatment of genetic diseases in biological samples.
1/2013Attenuation of nonsense-mediated mRNA decay enhances in vivo nonsense suppression.
12/2012Increased selectivity toward cytoplasmic versus mitochondrial ribosome confers improved efficiency of synthetic aminoglycosides in fixing damaged genes: a strategy for treatment of genetic diseases caused by nonsense mutations.
11/2011Suppression of CFTR premature termination codons and rescue of CFTR protein and function by the synthetic aminoglycoside NB54.
9/2011Post-transcriptionally regulated expression system in human xenogeneic transplantation models.
For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Timor Baasov Research Topics

Disease

17Inborn Genetic Diseases (Disease, Hereditary)
01/2017 - 12/2006
6Mucopolysaccharidosis I (Hurler Syndrome)
04/2016 - 05/2009
5Cystic Fibrosis (Mucoviscidosis)
04/2016 - 05/2009
4Usher Syndromes (Usher Syndrome)
04/2016 - 11/2007
2Leishmaniasis
09/2015 - 08/2013
2Ototoxicity
04/2014 - 01/2014
2Lysosomal Storage Diseases (Lysosomal Storage Disease)
03/2014 - 01/2012
2Rett Syndrome (Rett's Disorder)
04/2011 - 01/2011
2Duchenne Muscular Dystrophy (Muscular Dystrophy, Becker)
06/2010 - 05/2009
1Neoplasms (Cancer)
01/2017
1Body Weight (Weight, Body)
03/2016
1Glucose Intolerance
03/2016
1Visceral Leishmaniasis (Kala Azar)
09/2015
1Disease Progression
03/2014
1Retinal Degeneration
01/2014
1type 1C Usher syndrome
01/2014

Drug/Important Bio-Agent (IBA)

17AminoglycosidesIBA
01/2017 - 12/2006
15Nonsense Codon (Nonsense Mutation)IBA
01/2017 - 11/2007
6Gentamicins (Gentamicin)FDA LinkGeneric
01/2017 - 05/2009
5Anti-Bacterial Agents (Antibiotics)IBA
09/2015 - 09/2007
3antibiotic G 418IBA
01/2017 - 03/2013
3DNA (Deoxyribonucleic Acid)IBA
04/2016 - 05/2009
3Iduronidase (alpha-L-Iduronidase)IBA
03/2014 - 01/2012
1Glucose (Dextrose)FDA LinkGeneric
03/2016
1gamma-Aminobutyric Acid (GABA)IBA
03/2016
1Paromomycin (Paromomycin Sulfate)FDA LinkGeneric
09/2015
1Proteins (Proteins, Gene)FDA Link
01/2014
1atalurenIBA
01/2014
1Zinc Finger NucleasesIBA
01/2014
1apramycinIBA
08/2013
1Biological ProductsIBA
03/2013
1GlycosaminoglycansIBA
01/2012
1Terminator Codon (Termination Codon)IBA
09/2011
1Methyl-CpG-Binding Protein 2IBA
01/2011

Therapy/Procedure

7Therapeutics
01/2017 - 04/2011